Drug intelligence / Profile preview

BV2

Development stage: Preclinical
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

BV2 is a second bivalent SARS-CoV-2 mRNA vaccine, specifically targeting Ancestral and Omicron BA.4/5 variants. It was administered to older adults in long-term care and retirement homes in Ontario, Canada, during 2022-2023. The vaccine induced cross-reactive antibody and T cell responses. Humoral and cellular immune responses after two heterogenous bivalent vaccines (including BV2) were noninferior to those after a single bivalent vaccine within four months of vaccination.

Other names: Ancestral/Omicron BA.4/5 SARS-CoV-2 mRNA vaccinesecond bivalent vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on BV2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BV2.

Explore the full profile